Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IT-IO: Intrathecal Nivolumab and Ipilimumab for Leptomeningeal Metastasis
NCT05598853Phase 1Active, not recruiting
- Sponsor
- University of Zurich
- Start
- Nov 2022
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab and ipilimumab in leptomeningeal metastasis (LM), sponsored by University of Zurich. Primary endpoint: Recommended Phase II Dose at 3 weeks. Started Nov 2022; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
leptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT05598853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05598853.